

NexoBrid®

Disruptive Therapy for
Burn Care FDA and EMA approved



- Approved in 40+ countries
- 16,000+ patients treated to date
- Poised to replace standard of care for eschar removal in severe burns
- Minimizes need for surgery and significantly reduces blood loss
- Topical application at bedside
- Preserves viable tissue and improves patient outcomes (scar quality and function)
- c-GMP sterile manufacturing facility to support global demand

EscharEx®

Bioactive Enzymatic
Debridement Drug Candidate for Chronic Wounds



- Rapid, effective debridement and facilitation of wound closure
- Easy to use topical application for all patient settings
- Debrides chronic ulcers within 4-8 applications
- Promotes granulation tissue and reduces bacteria & biofilm
- Demonstrated superiority over SANTYL®
- Targets a \$2.5B+ market
- De-risked program; based on 3 successful Phase II trials
 - Ongoing Phase III trial for venous leg ulcers (VLU)
 - Trial for diabetic foot ulcers (DFU) planned H2 2026
 - Pressure ulcers (PU) Investigator-Initiated Trial (IIT) planned H2 2026
- Research collaborations with Mölnlycke, Solventum, Essit B. Braun, Coloplast, Convatec and MIMEDX

Global Collaborations



Validated Enzymatic Technology Platform

Solid Balance Sheet

\$54M cash (as of Dec. 31 2025)

\$17M revenues in 2025

\$120M BARDA funding (to date)

\$18M DoW funding (to date)